Loading oncology approvals…
Loading oncology approvals…
Regulatory
Every record is one authority's decision for one application or DIN, shown with its jurisdiction, date, indication text as published and status. A molecule approved in one jurisdiction for one indication is not 'approved' in general.
RegulatoryDevelopment pipeline →Methodology
Coverage
Counts of records, not of drugs approved: one application can carry several dated records (original approval, efficacy supplements, one row per DIN in Canada).
Approval records
4,342
Distinct drugs
373
Records naming a cancer
982
Dated in the last 12 months
179
| Authority | Jurisdiction | Records | Drugs | In force | Withdrawn / cancelled | Last 12 months | Latest dated record |
|---|---|---|---|---|---|---|---|
| FDA | US | 2,343 | 304 | 2,343 | 0 | 115 | Sep 18, 2026 |
| Health Canada | CA | 1,538 | 273 | 979 | 559 | 44 | Sep 22, 2026 |
| EMA | EU | 461 | 246 | 386 | 75 | 20 | Sep 18, 2026 |
Data updated yesterdaySource updated unknown3 authority · jurisdiction pairs ingested
Feed
Latest approval date first; records without a date are listed last. Filters combine.
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Feb 13, 2017 | Carfilzomib | Health Canada CA | cancer not stated in this record | Marketed in Canada as KYPROLIS (DIN 02459930) under ATC L01XG02 CARFILZOMIB. Indications are not published in the Drug Product Database —… | DIN02459930 | approvedsource: Marketed | health-canada-dpd |
| Feb 6, 2017 | Carfilzomib | Health Canada CA | cancer not stated in this record | Marketed in Canada as KYPROLIS (DIN 02459949) under ATC L01XG02 CARFILZOMIB. Indications are not published in the Drug Product Database —… | DIN02459949 | approvedsource: Marketed | health-canada-dpd |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jan 3, 2017 | Panitumumab | Health Canada CA | cancer not stated in this record | Marketed in Canada as VECTIBIX (DIN 02308509) under ATC L01FE02 PANITUMUMAB. Indications are not published in the Drug Product Database —… | DIN02308509 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Nov 28, 2016 | Filgrastim | Health Canada CA | cancer not stated in this record | Marketed in Canada as GRASTOFIL (DIN 02454548) under ATC L03AA02 FILGRASTIM. Indications are not published in the Drug Product Database —… | DIN02454548 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Oct 31, 2016 | Venetoclax | Health Canada CA | cancer not stated in this record | Marketed in Canada as VENCLEXTA (DIN 02458063) under ATC L01XX52 VENETOCLAX. Indications are not published in the Drug Product Database —… | DIN02458063 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Sep 22, 2016 | Abiraterone Acetate | Health Canada CA | cancer not stated in this record | Marketed in Canada as ZYTIGA (DIN 02457113) under ATC L02BX03 ABIRATERONE. Indications are not published in the Drug Product Database — see… | DIN |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Aug 26, 2016 | Glatiramer | Health Canada CA | cancer not stated in this record | Marketed in Canada as COPAXONE (DIN 02456915) under ATC L03AX13 GLATIRAMER ACETATE. Indications are not published in the Drug Product… | DIN02456915 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jul 28, 2016 | Erlotinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as PMS-ERLOTINIB (DIN 02454394) under ATC L01EB02 ERLOTINIB. Indications are not published in the Drug Product Database… | DIN02454394 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jun 2, 2016 | Docetaxel | Health Canada CA | cancer not stated in this record | Marketed in Canada as DOCETAXEL INJECTION (DIN 02439336) under ATC L01CD02 DOCETAXEL. Indications are not published in the Drug Product… | DIN02439336 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| May 16, 2016 | Olaparib | Health Canada CA | cancer not stated in this record | Marketed in Canada as LYNPARZA (DIN 02454408) under ATC L01XK01 OLAPARIB. Indications are not published in the Drug Product Database — see… | DIN02454408 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Apr 20, 2016 | Palbociclib | Health Canada CA | cancer not stated in this record | Marketed in Canada as IBRANCE (DIN 02453150) under ATC L01EF01 PALBOCICLIB. Indications are not published in the Drug Product Database —… | DIN02453150 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Mar 31, 2016 | Lenvatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as LENVIMA (DIN 02450321) under ATC L01EX08 LENVATINIB. Indications are not published in the Drug Product Database — see… | DIN02450321 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Feb 19, 2016 | Fluorouracil | Health Canada CA | cancer not stated in this record | Marketed in Canada as ACTIKERALL (DIN 02428946) under ATC L01BC52 FLUOROURACIL, COMBINATIONS. Indications are not published in the Drug… | DIN |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jan 28, 2016 | Filgrastim | Health Canada CA | cancer not stated in this record | Marketed in Canada as NEUPOGEN (DIN 02420104) under ATC L03AA02 FILGRASTIM. Indications are not published in the Drug Product Database —… | DIN02420104 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Dec 17, 2015 | Oxaliplatin | Health Canada CA | cancer not stated in this record | Marketed in Canada as OXALIPLATIN (DIN 02444763) under ATC L01XA03 OXALIPLATIN. Indications are not published in the Drug Product Database… | DIN02444763 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Nov 17, 2015 | Topotecan | Health Canada CA | cancer not stated in this record | Marketed in Canada as TEVA-TOPOTECAN (DIN 02441071) under ATC L01CE01 TOPOTECAN. Indications are not published in the Drug Product Database… | DIN02441071 |
A record is one authority's decision for one application/DIN; the same molecule appears once per jurisdiction and indication. Health Canada DPD does not publish indications — its records state the brand, DIN and ATC class only, and a cancelled or dormant DIN is the status of one product, not of the molecule. FDA cancer mappings come from label text and are flagged probabilistic on the drug page.
| approvedsource: Marketed |
| health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Nov 22, 2016 | Rituximab | Health Canada CA | cancer not stated in this record | Marketed in Canada as RITUXAN SC (DIN 02457350) under ATC L01FA01 RITUXIMAB. Indications are not published in the Drug Product Database —… | DIN02457350 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Oct 31, 2016 | Venetoclax | Health Canada CA | cancer not stated in this record | Marketed in Canada as VENCLEXTA (DIN 02458055) under ATC L01XX52 VENETOCLAX. Indications are not published in the Drug Product Database —… | DIN02458055 | approvedsource: Marketed | health-canada-dpd |
| Oct 31, 2016 | Venetoclax | Health Canada CA | cancer not stated in this record | Marketed in Canada as VENCLEXTA (DIN 02458047) under ATC L01XX52 VENETOCLAX. Indications are not published in the Drug Product Database —… | DIN02458047 | approvedsource: Marketed | health-canada-dpd |
| Oct 31, 2016 | Venetoclax | Health Canada CA | cancer not stated in this record | Marketed in Canada as VENCLEXTA (DIN 02458039) under ATC L01XX52 VENETOCLAX. Indications are not published in the Drug Product Database —… | DIN02458039 | approvedsource: Marketed | health-canada-dpd |
| Oct 14, 2016 | Alectinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as ALECENSARO (DIN 02458136) under ATC L01ED03 ALECTINIB. Indications are not published in the Drug Product Database —… | DIN02458136 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Sep 21, 2016 | Ixazomib | Health Canada CA | cancer not stated in this record | Marketed in Canada as NINLARO (DIN 02456826) under ATC L01XG03 IXAZOMIB. Indications are not published in the Drug Product Database — see… | DIN02456826 | approvedsource: Marketed | health-canada-dpd |
| Sep 21, 2016 | Ixazomib | Health Canada CA | cancer not stated in this record | Marketed in Canada as NINLARO (DIN 02456818) under ATC L01XG03 IXAZOMIB. Indications are not published in the Drug Product Database — see… | DIN02456818 | approvedsource: Marketed | health-canada-dpd |
| Sep 21, 2016 | Ixazomib | Health Canada CA | cancer not stated in this record | Marketed in Canada as NINLARO (DIN 02456796) under ATC L01XG03 IXAZOMIB. Indications are not published in the Drug Product Database — see… | DIN02456796 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Jul 28, 2016 | Erlotinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as PMS-ERLOTINIB (DIN 02454386) under ATC L01EB02 ERLOTINIB. Indications are not published in the Drug Product Database… | DIN02454386 | withdrawnsource: Dormantsince Jul 31, 2025 | health-canada-dpd |
| Jul 19, 2016 | Osimertinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as TAGRISSO (DIN 02456222) under ATC L01EB04 OSIMERTINIB. Indications are not published in the Drug Product Database —… | DIN02456222 | approvedsource: Marketed | health-canada-dpd |
| Jul 19, 2016 | Osimertinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as TAGRISSO (DIN 02456214) under ATC L01EB04 OSIMERTINIB. Indications are not published in the Drug Product Database —… | DIN02456214 | approvedsource: Marketed | health-canada-dpd |
| Jul 12, 2016 | Daratumumab | Health Canada CA | cancer not stated in this record | Marketed in Canada as DARZALEX (DIN 02455978) under ATC L01FC01 DARATUMUMAB. Indications are not published in the Drug Product Database —… | DIN02455978 | approvedsource: Marketed | health-canada-dpd |
| Jul 12, 2016 | Daratumumab | Health Canada CA | cancer not stated in this record | Marketed in Canada as DARZALEX (DIN 02455951) under ATC L01FC01 DARATUMUMAB. Indications are not published in the Drug Product Database —… | DIN02455951 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| withdrawnsource: Cancelled Post Marketsince Jan 11, 2021 |
| health-canada-dpd |
| May 2, 2016 | Gemcitabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as ACT GEMCITABINE (DIN 02433117) under ATC L01BC05 GEMCITABINE. Indications are not published in the Drug Product… | DIN02433117 | withdrawnsource: Cancelled Post Marketsince Aug 13, 2019 | health-canada-dpd |
| withdrawnsource: Cancelled Post Marketsince Jun 6, 2024 |
| health-canada-dpd |
| Apr 19, 2016 | Palbociclib | Health Canada CA | cancer not stated in this record | Marketed in Canada as IBRANCE (DIN 02453177) under ATC L01EF01 PALBOCICLIB. Indications are not published in the Drug Product Database —… | DIN02453177 | withdrawnsource: Cancelled Post Marketsince Jun 6, 2024 | health-canada-dpd |
| Apr 19, 2016 | Palbociclib | Health Canada CA | cancer not stated in this record | Marketed in Canada as IBRANCE (DIN 02453169) under ATC L01EF01 PALBOCICLIB. Indications are not published in the Drug Product Database —… | DIN02453169 | withdrawnsource: Cancelled Post Marketsince Jun 6, 2024 | health-canada-dpd |
| Apr 6, 2016 | Cobimetinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as COTELLIC (DIN 02452340) under ATC L01EE02 COBIMETINIB. Indications are not published in the Drug Product Database —… | DIN02452340 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Mar 31, 2016 | Lenvatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as LENVIMA (DIN 02450313) under ATC L01EX08 LENVATINIB. Indications are not published in the Drug Product Database — see… | DIN02450313 | approvedsource: Marketed | health-canada-dpd |
| Mar 31, 2016 | Lenvatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as LENVIMA (DIN 02450305) under ATC L01EX08 LENVATINIB. Indications are not published in the Drug Product Database — see… | DIN02450305 | approvedsource: Marketed | health-canada-dpd |
| Mar 31, 2016 | Lenvatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as LENVIMA (DIN 02450291) under ATC L01EX08 LENVATINIB. Indications are not published in the Drug Product Database — see… | DIN02450291 | approvedsource: Marketed | health-canada-dpd |
| Mar 17, 2016 | Blinatumomab | Health Canada CA | cancer not stated in this record | Marketed in Canada as BLINCYTO (DIN 02450283) under ATC L01FX07 BLINATUMOMAB. Indications are not published in the Drug Product Database —… | DIN02450283 | approvedsource: Marketed | health-canada-dpd |
| Mar 17, 2016 | Filgrastim | Health Canada CA | cancer not stated in this record | Marketed in Canada as GRASTOFIL (DIN 02441489) under ATC L03AA02 FILGRASTIM. Indications are not published in the Drug Product Database —… | DIN02441489 | approvedsource: Marketed | health-canada-dpd |
| Mar 4, 2016 | Sodium Iodide 131 I | Health Canada CA | cancer not stated in this record | Marketed in Canada as SODIUM IODIDE (131I) SOLUTION (DIN 02439905) under ATC V10XA01 SODIUM IODIDE 131 I. Indications are not published in… | DIN02439905 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Feb 11, 2016 | Carfilzomib | Health Canada CA | cancer not stated in this record | Marketed in Canada as KYPROLIS (DIN 02451034) under ATC L01XG02 CARFILZOMIB. Indications are not published in the Drug Product Database —… | DIN02451034 | approvedsource: Marketed | health-canada-dpd |
| Feb 2, 2016 | Filgrastim | Health Canada CA | cancer not stated in this record | Marketed in Canada as NEUPOGEN (DIN 02420112) under ATC L03AA02 FILGRASTIM. Indications are not published in the Drug Product Database —… | DIN02420112 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Jan 13, 2016 | Temozolomide | Health Canada CA | cancer not stated in this record | Marketed in Canada as ACH-TEMOZOLOMIDE (DIN 02438119) under ATC L01AX03 TEMOZOLOMIDE. Indications are not published in the Drug Product… | DIN02438119 | approvedsource: Marketed | health-canada-dpd |
| Jan 7, 2016 | Ponatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as ICLUSIG (DIN 02437341) under ATC L01EA05 PONATINIB. Indications are not published in the Drug Product Database — see… | DIN02437341 | withdrawnsource: Dormantsince Aug 8, 2022 | health-canada-dpd |
| Jan 2, 2016 | Oxaliplatin | Health Canada CA | cancer not stated in this record | Marketed in Canada as OXALIPLATIN INJECTION (DIN 02436167) under ATC L01XA03 OXALIPLATIN. Indications are not published in the Drug Product… | DIN02436167 | approved | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Dec 17, 2015 | Oxaliplatin | Health Canada CA | cancer not stated in this record | Marketed in Canada as OXALIPLATIN INJECTION (DIN 02436957) under ATC L01XA03 OXALIPLATIN. Indications are not published in the Drug Product… | DIN02436957 | approvedsource: Marketed | health-canada-dpd |
| Dec 16, 2015 | Oxaliplatin | Health Canada CA | cancer not stated in this record | Marketed in Canada as PMS-OXALIPLATIN (DIN 02437074) under ATC L01XA03 OXALIPLATIN. Indications are not published in the Drug Product… | DIN02437074 | withdrawnsource: Cancelled Post Marketsince Jul 4, 2025 | health-canada-dpd |
| Dec 16, 2015 | Oxaliplatin | Health Canada CA | cancer not stated in this record | Marketed in Canada as OXALIPLATIN INJECTION (DIN 02435071) under ATC L01XA03 OXALIPLATIN. Indications are not published in the Drug Product… | DIN02435071 | approvedsource: Marketed | health-canada-dpd |
| Dec 16, 2015 | Oxaliplatin | Health Canada CA | cancer not stated in this record | Marketed in Canada as ACT OXALIPLATIN (DIN 02432617) under ATC L01XA03 OXALIPLATIN. Indications are not published in the Drug Product… | DIN02432617 | withdrawnsource: Cancelled Post Marketsince Jul 9, 2018 | health-canada-dpd |
| Dec 8, 2015 | Temozolomide | Health Canada CA | cancer not stated in this record | Marketed in Canada as TEVA-TEMOZOLOMIDE (DIN 02441160) under ATC L01AX03 TEMOZOLOMIDE. Indications are not published in the Drug Product… | DIN02441160 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Nov 17, 2015 | Bortezomib | Health Canada CA | cancer not stated in this record | Marketed in Canada as ACT BORTEZOMIB (DIN 02438399) under ATC L01XG01 BORTEZOMIB. Indications are not published in the Drug Product… | DIN02438399 | approvedsource: Marketed | health-canada-dpd |